CSV February 22, 2023 through February 22, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ALCOHOLOME	INTRODUCTIO	*USPNF 2021*	Online	27-Aug-2021	1-Dec-2021	*NA*	*NA*	Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TRIC TABLE	N	*ISSUE 3*						Similarly, a specific gravity value of 0.8092 in column *1* corresponds to a solution that contains 95% alcohol by weight or 92.42% alcohol v/v. to: Similarly, a specific gravity value of 0.8092 in column *1* corresponds to a solution that contains 95% alcohol v/v or 92.42% alcohol by weight.
LUMEFANTRINE	CHEMICAL INFORMATION	*USPNF 2021 ISSUE 1*	Online	27-Aug-2021	1-Sep-2021	*NA*	*NA*	Change (±)-2,7-Dichloro-9-[(Z)-*p*-chlorobenzylidine]-?[(dibutylamino)methyl]-fluorene-4-methanol to: (±)-2,7-Dichlor

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								o-9-[(Z) -*p* -chlorobenzylidene]-?-[(dibutylamino)methyl]-fluorene-4-methanol
ZIPRASIDONE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	4699	30-Jul-2021	1-Aug-2021	*NA*	*NA*	In USP Ziprasidone Related Compound F RS: Change 2-(2-Amino-5-{2-[4-(benzo[*d*]isothiazol-3-yl)piperazin-1-yl]ethyl}-4-chlorophenyl)acetic acid. $C_{21}H_{23}ClN_4O_2S$ 430.95 to: Sodium 2-(2-amino-5-{2-[4-(benzisothiazol-3-yl)piperazin-1-yl]ethyl}-4-chlorophenyl)acetate monohydrate; Also known as Sodium 2-(2-am

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ino-5-{2-[4-(ben zo[*d*]isothiazol-3-yl) piperazin-1-yl]et hyl}-4-chlorophe nyl)acetate monohydrate. $C_{21}H_{22}ClN_4$ $NaO_2S \cdot H_2O$ 470.95
PRODUCTS FOR NEBULIZ ATION—CHARA CTERIZATION TESTS	AERODYNAMI C ASSESSMENT OF NEBULIZED AEROSOLS	*USP43–NF38*	8407	30-Jul-2021	1-Aug-2021	*NA*	*NA*	Change Apparatus 5 (see general chapter *Inhalation and Nasal Drug Products: Aerosols, Sprays, and Po wders—Perform ance Quality Tests* ?601?), a cascade impactor, has been calibrated at 15 L/min specifically to meet the recom mendation of the CEN Standard and is

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								therefore used for this test.[3] to: The Next Generation Impactor without pre-separator used with inhalation aerosols, inhalation sprays, and nasal aerosols is described in *Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders—Performance Quality Tests* ?601?. An archival version of this cascade impactor has been calibrated at 15 L/min specifically to meet the recommendation of the CEN

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Standard and this configuration is therefore used for this test.[3] AND In *Apparatus*: Change A detailed description of Apparatus 5 and the induction port is contained in ?601?, and includes details of to: *Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders—Performance Quality Tests* <601>, *C.4 Next Generation Impactor without Pre-separator for*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Inhalation Aerosols, Inhalation Sprays, and Nasal Aerosols includes details of AND In *Procedure*: Change *Figure 2. Apparatus 5 for Measuring the Size Distribution of Products for Nebulization.* to: *Figure 2. Next Generation Impactor without Pre-separator for Measuring the Size Distribution of Products for Nebulization.* AND In *Procedure*: Change on the back-up filter as

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								described for Apparatus 5 (see ?601?). to: on the back-up filter as described in *Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders—Performance Quality Tests <601>, C.4 Next Generation Impactor without Pre-separator for Inhalation Aerosols, Inhalation Sprays, and Nasal Aerosols*. AND In *Procedure*: Change Determine the cumulative mass-weighted

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								particle-size distribution of the aerosol size-fractionated by the impactor in accordance with the procedure given in ?601?. to: Determine the cumulative mass-weighted particle-size distribution of the aerosol size-fractionated by the impactor in accordance with the procedure given in *Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders—Performance Quality Tests* <601>, *C.4 Next Generation Impactor*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								without Pre-separator for Inhalation Aerosols, Inhalation Sprays, and Nasal Aerosols. AND In *Table 2*: Change *Table 2. Cut-off Sizes for Apparatus 5 at 15 L/min* to: *Table 2. Cut-off Sizes for Next Generation Impactor without Pre-separator at 15 L/min*
MYCOPHENOLATE MOFETIL TABLETS	PERFORMANCE TESTS/ *Dissolution* <711>	*USP43–NF38*	3049	30-Jul-2021	1-Aug-2021	*NA*	*NA*	In *Test 3*/*Analysis*: Change Result = $(r_U/r_S) \times C_S \times D$ r_U = peak response from the *Sample solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								r_S = peak response from the *Standard solution* C_S = concentration of the *Standard solution* (mg/mL) D = dilution factor of the *Sample solution*, 50 to: Result = $(A_U/A_S) \times C_S \times D$ A_U = absorbance from the *Sample solution* A_S = absorbance from the *Standard solution* C_S = concentration of the *Standard solution* (mg/mL) D = dilution

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								factor of the *Sample solution*, 50
GEMCITABINE FOR INJECTION	IMPURITIES/*Organic Impurities*	*USP43–NF38*	2094	30-Jul-2021	1-Aug-2021	*NA*	*NA*	In *Table 2*: Change Cytosine[a] to: Cytosine AND Delete footnote a AND Update footnote order
Zinc Acetate	REAGENTS AND REFERENCE TABLES/*Reagent Specifications*	*USP43–NF38*	6219	30-Jul-2021	1-Aug-2021	*NA*	*NA*	Change [557-34-6]. to: [5970-45-6].
GEMCITABINE HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*USP43–NF38*	2093	30-Jul-2021	1-Aug-2021	*NA*	*NA*	In *Table 2*: Change Cytosine[a] to: Cytosine AND Delete footnote a AND Update footnote order

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
QUAZEPAM	ADDITIONAL REQUIREMENTS/*USP Reference standards <11>*	*USP43–NF38*	3790	30-Jul-2021	1-Aug-2021	*NA*	*NA*	In USP Quazepam Related Compound A RS: Change 7-Chloro-1-(2,2,2 trifluoroethyl)-5-(2-Fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepine-2-one. to: 7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2*H*-1,4-benzodiazepine-2-one.
PRODUCTS FOR NEBULIZATION—CHARACTERIZATION TESTS	AERODYNAMIC ASSESSMENT OF NEBULIZED AEROSOLS	*USP43–NF38*	8407	30-Jul-2021	1-Aug-2021	*NA*	*NA*	Please see the updated *Figure 2* at online.uspnf.com
CODEINE PHOSPHATE TABLETS	*Identification*	*USP43–NF38*	1139	30-Jul-2021	1-Aug-2021	*NA*	*NA*	In *A*.: Change Render the filtrate alkaline with 6 N ammonium hydroxide,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								extract with several small portions of chloroform, and proceed as directed in *Identification* test *A* under *Codeine Phosphate Injection*, beginning with “Evaporate the combined chloroform extracts.” The specified results are observed. to: Render the filtrate alkaline with 6 N ammonium hydroxide and extract with several small portions of chloroform. Evaporate the combined chloroform

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								extracts on a steam bath to dryness, and dry at 80° for 4 hours: the IR absorption spectrum of a potassium bromide dispersion of the residue so obtained exhibits maxima at the same wavelengths as that of the codeine obtained by similarly treating 1 mL of a solution of USP Codeine Phosphate RS (1 in 100).
GEMCITABINE FOR INJECTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	2094	30-Jul-2021	1-Aug-2021	*NA*	*NA*	In USP Cytosine RS: Change 2(1*H*)-Pyrimidinone, 4-amino-. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DORZOLAMIDE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	1496	30-Jul-2021	1-Aug-2021	*NA*	*NA*	Cytosine. In USP Dorzolamide Hydrochloride Related Compound A RS: Change 360.91 to 360.89
ONDANSETRON INJECTION	*Assay*	*USP43–NF38*	3265	30-Jul-2021	1-Aug-2021	*NA*	*NA*	In *Chromatographic system*: Change The liquid chromatograph is equipped with a 216-nm detector and a 4.6-mm × 20-cm column that contains packing L10. to: The liquid chromatograph is equipped with a 216-nm detector and a 4.6-mm × 25-cm column

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								that contains packing L10.
GEMCITABINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	2093	30-Jul-2021	1-Aug-2021	*NA*	*NA*	In USP Cytosine RS: Change 2(1*H*)-Pyrimidinone, 4-amino-. to: Cytosine.
QUAZEPAM TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference standards <11>*	*USP43–NF38*	3791	30-Jul-2021	1-Aug-2021	*NA*	*NA*	In USP Quazepam Related Compound A RS: Change 7-Chloro-1-(2,2,2 trifluoroethyl)-5-(2-Fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepine-2-one. to: 7-Chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2*H*-1,4-benzodiazepine-2-one.
CODEINE PHOSPHATE	*Limit of morphine*	*USP43–NF38*	1139	30-Jul-2021	1-Aug-2021	*NA*	*NA*	Change A 1-mL portion

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLETS								of the filtrate from *Identification* test *B* meets the requirements of the test for *Limit of morphine* under *Codeine Phosphate*. to: Dissolve about 50 mg of potassium ferricyanide in 10 mL of water, and add 1 drop of ferric chloride TS and a 1-mL portion of the filtrate from *Identification* test *B*: no blue color is produced immediately.
CLOZAPINE	IM PUR ITIES/*Organic Impurities*	*USPNF 2021 ISSUE 1*	Online	25-Jun-2021	1-Jul-2021	*NA*	*NA*	In *Table 2*: Change Demethyl clozapin to: Demethyl

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								clozapine
DACTINOMYCIN	CHEMICAL INFORMATION	*USP43–NF38*	Online	25-Jun-2021	1-Jul-2021	*NA*	*NA*	Please see the updated chemical structure at online.uspnf.com
AMIODARONE HYDROCHLORIDE INJECTION	IM PURITIES/*Limit of Iodide*	*USP43–NF38*	254	25-Jun-2021	1-Jul-2021	*NA*	*NA*	In *Potassium iodate solution*: Change 10.7 g/L of potassium iodide in water to: 10.7 g/L of potassium iodate in water
AMITRIPTYLINE HYDROCHLORIDE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	263	25-Jun-2021	1-Jul-2021	*NA*	*NA*	In USP Amitriptyline Related Compound B RS: Change 295.42 to: 295.43
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE TABLETS	ADDITIONAL REQUIREMENTS/*USP References Standards <11>*	*Revision Bulletin (Official May 01, 2021)*	Online	25-Jun-2021	1-Jul-2021	*NA*	*NA*	In USP Benazepril Related Compound B RS: Change (3*S*) 3-[[(1*R*) 1-(Ethoxycarbonyl)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1*H*-1-benzazepine-1-acetic acid, monohydrochloride; Also known as 2-[(*SR*)-3-{[(*RS*)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepin-1-yl]acetic acid hydrochloride. to: 2-[(*S*)-3-{[(*R*)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepin-1-yl]acetic acid hydrochloride;

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Also known as (3*S*) 3-[[(1*R*)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1*H*-1-benzazepine-1-acetic acid, monohydrochloride.
KETOROLAC TROMETHAMINE	IMPURITIES/*Organic Impurities*	*USP43–NF38*	2513	25-Jun-2021	1-Jul-2021	*NA*	*NA*	Change *Mobile phase, Diluent, System suitability solution, Standard solution,* and *Sample solution*: Proceed as directed in the *Assay*. to: *Mobile phase, Diluent, System suitability solution, Standard solution,*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Sample solution, and *System suitability*: Proceed as directed in the *Assay*.
BENAZEPRIL HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP References standards <11>*	*USP43–NF38*	488	25-Jun-2021	1-Jul-2021	*NA*	*NA*	In USP Benazepril Related Compound A RS: Change (3*R*) 3-[[(1*R*) 1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1*H*-1-benzazepine-1-acetic acid, monohydrochloride. to: 2-[(*R*)-3-{[(*R*)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepin-1-yl]ace

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								tic acid hydrochloride; Also known as (3*R*) 3-[[(1*R*)-1-(Ethoxycarb onyl)-3-phenylpr opyl]amino]-2,3, 4,5-tetrahydro-2 -oxo-1*H* -1-benzazepine- 1-acetic acid, m onohydrochlorid e. AND In USP Benazepril Related Compound B RS: Change (3*S*) 3-[[(1*R*) 1-(Ethoxycarbonyl) -3-phenylpropyl] amino]-2,3,4,5-t etrahydro-2-oxo -1*H* -1-benzazepine- 1-acetic acid, m onohydrochlorid e. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								2-[(*S*)-3-{[(*R*)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepin-1-yl]acetic acid hydrochloride; Also known as (3*S*) 3-[[(1*R*)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1*H*-1-benzazepine-1-acetic acid, monohydrochloride. AND In USP Benazepril Related Compound C RS: Change 3-(1-Carboxy-3-phenyl -1(*S*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-propyl)amino-2,3,4,5-tetrahydro-2-oxo-1*H*-1-(3*S*)-benzazepine-1-acetic acid. to: (*S*)-2-{[(*S*)-1-(Carboxymethyl)-2-oxo-2,3,*H*-benzo[*b*]azepin-3-yl]amino}-4-phenylbutanoic acid; Also known as 3-(1-Carboxy-3-phenyl-1(*S*)-propyl)amino-2,3,4,5-tetrahydro-2-oxo-1*H*-1-(3*S*)-benzazepine-1-acetic acid. AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								In USP Benazepril Related Compound D RS: Change (3-(1-Ethoxycarbonyl-3-cyclohexyl-(1*S*)-propyl)amino-2,3,4,5-tetrahydro-2-oxo-1*H*-1-(3*S*)-benzazepine)-1-acetic acid, monohydrochloride. to: 2-[(*S*)-3-{[(*S*)-4-Cyclohexyl-1-ethoxy-1-oxobutan-2-yl]amino}-2-oxo-2,3,4,5-tetra hydro-1*H*-benzo[*b*]azepin-1-yl]acetic acid hydrochloride; Also known as (3-(1-Ethoxycarb

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								onyl-3-cyclohexyl-(1*S*)-propyl)amino-2,3,4,5-tetrahydro-2-oxo-1*H*-1-(3*S*)-benzazepine)-1-acetic acid, monohydrochloride. AND In USP Benazepril Related Compound ERS: Change 3-Amino-2,3,4,5-tetrahydro-2-oxo-1*H*-1-(3*S*)-benzazepine-1-acetic acid. to: (*S*)-2-(3-Amino-2-oxo-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepin-1-yl)acetic acid

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hydrochloride; Also known as 3-Amino-2,3,4,5-tetrahydro-2-oxo-1*H*-1-(3*S*)-benzazepine-1-acetic acid monohydrochloride. $C_{12}H_{14}N_2O_3 \cdot HCl$ 270.71 AND In USP Benazepril Related Compound F RS: Change *tert*-Butyl-3-amino-2,3,4,5-tetrahydro-2-oxo-1*H*-1-(3*S*)-benzazepine-1-acetic acid. to: *tert*-Butyl (*S*)-2-(3-amino-2-oxo-2,3,4,5-tetrahydro

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-1*H* -benzo[*b*]azepin-1-yl)acetate; Also known as *tert* -Butyl-3-amino-2,3,4,5-tetrahydro-2-oxo-1*H* -1-(3*S*)-benzazepine-1-acetic acid. $C_{16}H_{22}N_2O_3$ 290.36 AND In USP Benazepril Related Compound G RS: Change (3-(1-Ethoxycarbonyl-3-phenyl-(1*S*)-propyl)amino-2,3,4,5-tetrahydro-2-oxo-1*H* -1-(3*S*)-benzazepine)-1-acetic acid

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ethyl ester. to: Ethyl (*S*)-2-{[(*S*)-1-(2-ethoxy-2-oxoethyl)-2-oxo-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepin-3-yl]amino}-4-phenylbutanoate; Also known as (3-(1-Ethoxycarb
								S)-propyl)amino-2,3,4,5-tetrahydro-2-oxo-1*H*-1-(3*S*)-benzazepine)-1-acetic acid ethyl ester. $C_{26}H_{32}N_2O_5$ 452.55
METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS/	PERFORMANCE TESTS/	*Revision Bulletin (Official March 01,*	Online	25-Jun-2021	1-Jul-2021	*NA*	*NA*	In *Test 14/Analysis*: Delete

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
RELEASE TABLETS	*Dissolution <711>*	*2021)*						$Result_4 = \{(C_4 \times V) + [(C_3 + C_2 + C_1) \times V_S]\} \times (1/L) \times 100$
LANSOPRAZOLE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	2551	25-Jun-2021	1-Jul-2021	*NA*	*NA*	In USP Lansoprazole Related Compound B RS: Change 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-pyridin-2-yl] methyl]sulfanyl]-1*H*-benzimidazole. $C_{16}H_{14}F_3N_3OS$ 353.36 to: 2-{[(3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl]thio}benzimidazole monohydrate. $C_{16}H_{14}F_3N_3OS \cdot H_2O$ 371.38
GLYBURIDE	CHEMICAL INFORMATION	*USP43–NF38*	2125	25-Jun-2021	1-Jul-2021	*NA*	*NA*	Change 1-[[*p*-[2-(5-Chloro-*o*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-anisamido)ethyl]phenyl]sulfonyl]-3-cyclohex-ylurea to: 1-[[*p*-[2-(5-Chloro-*o*-anisamido)ethyl]phenyl]sulfonyl]-3-cyclohexylurea
NORTRIPTYLINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF 2021 ISSUE 1*	Online	25-Jun-2021	1-Jul-2021	*NA*	*NA*	In USP Amitriptyline Related Compound B RS: Change 295.42 to: 295.43
BENAZEPRIL HYDROCHLORIDE TABLETS	ADDITIONAL REQUIREMENTS/*USP References Standards <11>*	*USP43–NF38*	Online	25-Jun-2021	1-Jul-2021	*NA*	*NA*	In USP Benazepril Related Compound B RS: Change (3*S*)-3-[[(1*R*)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								4,5-tetrahydro-2-oxo-1*H*-1-benzazepine-1-acetic acid, monohydrochloride; Also known as 2-[(*SR*)-3-{[(*RS*)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepin-1-yl]acetic acid hydrochloride. to: 2-[(*S*)-3-{[(*R*)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1*H*-benzo[*b*]azepin-1-yl]acetic acid hydrochloride; Also known as (3*S*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-3-[[(1*R*)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1*H*-1-benzazepine-1-acetic acid, monohydrochloride.
AMITRIPTYLINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	Online	28-May-2021	1-Jun-2021	*NA*	*NA*	In USP Amitriptyline Related Compound B RS: Change 295.42 to: 295.43
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE TABLETS	ASSAY/*Procedure*	*USP43–NF38*	938	28-May-2021	1-Jun-2021	*NA*	*NA*	In *Analysis*: Change 313.86 to: 313.87
GARLIC FLUID EXTRACT	COMPOSITION/*Content of S-Allyl-L-cysteine*	*USP43–NF38*	5023	28-May-2021	1-Jun-2021	*NA*	*NA*	In *Analysis*: Change Calculate the percentage of *S*-allyl-L-cysteine ($C_6H_{11}SN$) in the portion of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Fluidextract taken: to: Calculate the percentage of *S*-allyl-L-cysteine in the portion of Fluidextract taken:
HYDROXYZINE PAMOATE	IMPURITIES/*Organic Impurities*	*USP43–NF38*	2269	28-May-2021	1-Jun-2021	*NA*	*NA*	In *System suitability/Suitability requirements/Resolution*: Change 4-chlorobenophenone to: 4-chlorobenzophenone
CARBOMER HOMOPOLYMER	CHEMICAL INFORMATION	*USPNF 2021 ISSUE 1*	Online	28-May-2021	1-Jun-2021	*NA*	*NA*	Please see the updated chemical structure at https://online.uspnf.com
GADOTERATE MEGLUMINE INJECTION	OTHER COMPONENTS/*Content of Meglumine*	*USPNF 2021 ISSUE 1*	Online	28-May-2021	1-Jun-2021	*NA*	*NA*	In *Analysis*: Change Result = (*a*/*?*) × (1/*l*) × (1/*L*) × 100

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CARBOMER COPOLYMER	IMPURITIES	*USPNF 2021 ISSUE 1*	Online	28-May-2021	1-Jun-2021	*NA*	*NA*	to: Result = (*a/?*) × 100 × (1/*l*) × (1/*L*) × 100 In *Limit of Ethyl Acetate and Cyclohexane/Analysis*: Change *Samples: Standard stock solution, Standard solution A, Standard solution B, Standard solution C,* and *Sample solution* to: *Samples: Standard solution A, Standard solution B, Standard solution C,* and *Sample solution* AND In *Limit of Benzene/Analysis*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Samples: *Standard stock solution, Standard solution A, Standard solution B, Standard solution C,* and *Sample solution* to: *Samples: Standard solution A, Standard solution B, Standard solution C,* and *Sample solution*
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP43–NF38*	938	28-May-2021	1-Jun-2021	*NA*	*NA*	In *Analysis*: Change 313.86 to: 313.87
BIFIDOBACTERIUM LONGUM SUBSP. LONGUM	DEFINITION	*USPNF 2021 ISSUE 1*	Online	28-May-2021	1-Jun-2021	*NA*	*NA*	Change *Bifidobacterium longum* subsp. *longum* comprises to: *Bifidobacterium*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								longum subsp. *longum* comprises
AMITRIPTYLINE HYDROCHLORIDE	CHEMICAL INFORMATION	*USP43–NF38*	Online	28-May-2021	1-Jun-2021	*NA*	*NA*	Change 313.86 to: 313.87
CARBOMER INTERPOLYMER	IMPURITIES	*USPNF 2021 ISSUE 1*	Online	28-May-2021	1-Jun-2021	*NA*	*NA*	In *Limit of Ethyl Acetate and Cyclohexane/Analysis*: Change *Samples: Standard stock solution, Standard solution A, Standard solution B, Standard solution C,* and *Sample solution* to: *Samples: Standard solution A, Standard solution B, Standard solution C,* and *Sample solution* AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								In *Limit of Benzene/Analysis*: Change *Samples: Standard stock solution, Standard solution A, Standard solution B, Standard solution C,* and *Sample solution* to: *Samples: Standard solution A, Standard solution B, Standard solution C,* and *Sample solution*
MINOXIDIL TABLETS	IMPURITIES/*Organic Impurities*	*USPNF 2021 ISSUE 1*	Online	28-May-2021	1-Jun-2021	*NA*	*NA*	In *Analysis*: Change Result = $(r_U/r_S) \times (C_U/C_S) \times 100$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times 100$
HYDROXYZINE PAMOATE	ASSAY/*Procedure*	*USP43–NF38*	2271	28-May-2021	1-Jun-2021	*NA*	*NA*	In *System suitability/Suitability r*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CAPSULES								*equirements/Resolution*: Change 4-chlorobenophenone, to: 4-chlorobenzophenone,
CARBOMER HOMOPOLYMER	IMPURITIES	*USPNF 2021 ISSUE 1*	Online	28-May-2021	1-Jun-2021	*NA*	*NA*	In *Limit of Ethyl Acetate and Cyclohexane/Analysis*: Change *Samples: Standard stock solution, Standard solution A, Standard solution B, Standard solution C,* and *Sample solution* to: *Samples: Standard solution A, Standard solution B, Standard solution C,* and *Sample solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND In *Limit of Benzene/Analysis*: Change *Samples: Standard stock solution, Standard solution A, Standard solution B, Standard solution C,* and *Sample solution* to: *Samples: Standard solution A, Standard solution B, Standard solution C,* and *Sample solution*
CLOZAPINE	CHEMICAL INFORMATION	*USPNF 2021 ISSUE 1*	Online	28-May-2021	1-Jun-2021	*NA*	*NA*	Change 326.82 to: 326.83
OIL- AND WATER-SOLUBLE VITAMINS WITH	STRENGTH	*USPNF 2021 ISSUE 1*	Online	30-Apr-2021	1-May-2021	*NA*	*NA*	In *Vitamins B3 (as Niacinamide), B6, and Folic*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MINERALS CHEWABLE GELS								*Acid, Method 1/System suitability*: Change [Note—The relative retention times for niacinamide, pyridoxine, and folic acid are about 1.0, 1.6, 2.0, and 3.0 respectively.] to: [Note—The relative retention times for niacinamide, pyridoxine, and folic acid are about 1.0, 2.0, and 3.0, respectively.] AND In *Vitamins B1 (as Thiamine Ion) and B2 (as Riboflavin), Method 1; Vitamin C (as Ascorbic Acid),*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Vitamins B3 (as Niacinamide), B6 (as Pyridoxine), and Folic Acid, Method 2/Analysis: Change Calculate the percentage of the labeled amount of vitamin B1 as thiamine ion ($C_{12}H_{17}N_4OS^+$), vitamin B2 as riboflavin ($C_{17}H_{20}N_4O_6$), vitamin B3 as niacinamide ($C_6H_6N_2O$), vitamin B6 as pyridoxine ($C_8H_{11}NO_3$), and folic acid ($C_{19}H_{19}N_7O_6$), in the portion of Chewable Gels taken: to: Calculate the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								percentage of the labeled amount of vitamin C as ascorbic acid ($C_6H_8O_6$), vitamin B1 as thiamine ion ($C_{12}H_{17}N_4OS^+$), vitamin B2 as riboflavin ($C_{17}H_{20}N_4O_6$), vitamin B3 as niacinamide ($C_6H_6N_2O$), vitamin B6 as pyridoxine ($C_8H_{11}NO_3$), and folic acid ($C_{19}H_{19}N_7O_6$), in the portion of Chewable Gels taken: AND In *Vitamins B1 (as Thiamine Ion) and B2 (as Riboflavin), Method 1; Vitamin C (as Ascorbic Acid),*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Vitamins B3 (as Niacinamide), B6 (as Pyridoxine), and Folic Acid, Method 2/Acceptance criteria: Change 90.0%–150.0% of the labeled amounts of vitamin B3 as niacinamide, vitamin B6 as pyridoxine, riboflavin, and thiamine as thiamine ion ($C_{12}H_{17}N_4OS^+$); and NLT 90.0% and NMT 245.0% of the labeled amount of folic acid to: 90.0%–250.0% of the labeled amount of vitamin C as ascorbic acid; 90.0%–150.0%

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								of the labeled amounts of vitamin B3 as niacinamide, vitamin B6 as pyridoxine, riboflavin, and thiamine as thiamine ion ($C_{12}H_{17}N_4OS^+$); and NLT 90.0% and NMT 245.0% of the labeled amount of folic acid
CARBOMER IN TERPOLYMER	CHEMICAL INFORMATION	*USPNF 2021 ISSUE 1*	Online	30-Apr-2021	1-May-2021	*NA*	*NA*	Please see the updated chemical structure at online.uspnf.com
DOXEPIN HYDROCHLORIDE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*	*Revision Bulletin (Official May 01, 2021)*	Online	30-Apr-2021	1-May-2021	*NA*	*NA*	In *Test 1/Analysis*: Change *L* = label claim of doxepin hydrochloride (mg/Capsule) to: *L* = label claim (mg/Capsule)
AZITHROMYCI	PERFORMANC	*USPNF 2021*	Online	30-Apr-2021	1-May-2021	*NA*	*NA*	In *Medium*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
N FOR ORAL SUSPENSION	E TESTS/ *Dissolution <711>*	*ISSUE 1*						Change Sodium phosphate buffer, pH of 6.0 (14.2 g/L of disodium hydrogen orthophosphate anhydrous in *water*, adjusted with dilute hydrochloric acid to a pH of 6.0) to: Sodium phosphate buffer, pH 6.0 (14.2 g/L of sodium phosphate, dibasic, anhydrous in water, adjusted with dilute hydrochloric acid to pH 6.0) AND In *Solution A*: Change orthophosphori

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								c acid to: phosphoric acid
MALTITOL SOLUTION	IM PURITIES/*Limit of Nickel*	*USPNF 2021 ISSUE 1*	Online	30-Apr-2021	1-May-2021	*NA*	*NA*	Change *Solution A*: [Note—Prepare this solution fresh weekly.] to: *Standard nickel solution A*: [Note—Prepare this solution fresh weekly.]
CARBOMER INTERPOLYMER	IM PURITIES/*Limit of Acrylic Acid*	*USPNF 2021 ISSUE 1*	Online	30-Apr-2021	1-May-2021	*NA*	*NA*	In *Analysis*: Change C_U = concentration of Carbomer Interpolymer in the *Sample solution* (g) to: C_U = concentration of Carbomer Interpolymer in the *Sample solution* (mg/g)

- First page « First
- Previous page ‹ Previous
- …
- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- Page 10
- Page 11
- Page 12
- Page 13
- …
- Next page Next ›
- Last page Last »